Significant Differences in CVD Risk Factors Between Men and Women with Type 2 Diabetes

NEW ROCHELLE, N.Y. - May 15, 2014 - PRLog -- New Rochelle, NY—Type 2 diabetes greatly increases a person’s risk of developing cardiovascular disease (CVD). A new study showing that cardiovascular risk factors such as elevated blood pressure and cholesterol levels differ significantly between men and women is published in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the DTT website at http://www.liebertpub.com/dtt.

Joni Strom Williams, MD, MPH and coauthors from Medical University of South Carolina and Ralph H. Johnson VA Medical Center (Charleston, SC), compared three individual CVD risk factors and a “composite control” factor (comprised of all three risk factors together) among a group of men and women with type 2 diabetes. In the article “Gender Differences in Composite Control of Cardiovascular Risk Factors Among Patients with Type 2 Diabetes” (http://online.liebertpub.com/doi/full/10.1089/dia.2013.0329) the authors report significant disparities for blood pressure, low-density lipoprotein (LDL) cholesterol, and composite control, but not for control of glycosylated hemoglobin A1c.

“Cardiovascular disease continues to be a significant factor for increased morbidity and mortality in people with type 2 diabetes,” says DTT Editor-in-Chief Satish Garg, MD, Professor of Medicine and Pediatrics at the University of Colorado Denver. “Every attempt should be made to reduce gender differences as they relate to co-morbidities.”

About the Journal
Diabetes Technology & Therapeutics (DTT) is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, Professor of Medicine and Pediatrics at the University of Colorado Denver, the Journal covers topics that include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of content and a sample issue may be viewed on the Diabetes Technology & Therapeutics (DTT) website at http://www.liebertpub.com/dtt. DTT is the official journal of the Advanced Technologies & Treatments for Diabetes (ATTD) Conference.

About ATTD
The International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) presents top-caliber scientific programs that have provided participants with cutting-edge research and analysis into the latest developments in diabetes-related technology. A unique and innovative conference, ATTD brings the world’s leading researchers and clinicians together for a lively exchange of ideas and information related to the technology, treatment, and prevention of diabetes and related illnesses.

About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Thyroid, Metabolic Syndrome and Related Disorders, Journal of Aerosol Medicine and Pulmonary Drug Delivery, Childhood Obesity, and Population Health Management. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website at http://www.liebertpub.com.

Mary Ann Liebert, Inc.    140 Huguenot St., New Rochelle, NY 10801-5215    www.liebertpub.com
Phone: (914) 740-2100    (800) M-LIEBERT    Fax:  (914) 740-2101